An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
14
04
2021
received:
28
01
2021
accepted:
16
04
2021
pubmed:
19
8
2021
medline:
23
2
2022
entrez:
18
8
2021
Statut:
ppublish
Résumé
CD70 is expressed in up to 80% of nasopharyngeal carcinoma (NPC) cases. Cusatuzumab is a humanized anti-CD70 monoclonal antibody, with dual action mechanisms: induction of cytotoxicity against CD70
Identifiants
pubmed: 34405542
doi: 10.1111/cts.13089
pmc: PMC8604223
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
CD27 Ligand
0
CD70 protein, human
0
Immunologic Factors
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2300-2313Informations de copyright
© 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Br J Cancer. 2017 Dec 5;117(12):1743-1752
pubmed: 29065104
Pharmacol Ther. 2015 Nov;155:1-10
pubmed: 26213107
Br J Cancer. 2010 Aug 24;103(5):676-84
pubmed: 20664585
J Exp Med. 2017 Jan;214(1):73-89
pubmed: 28011863
Clin Cancer Res. 2017 Nov 1;23(21):6411-6420
pubmed: 28765328
J Immunol. 1994 Feb 15;152(4):1756-61
pubmed: 8120384
Cancer Med. 2020 Mar;9(5):1721-1732
pubmed: 31955525
J Immunol. 1994 Feb 15;152(4):1762-73
pubmed: 8120385
MAbs. 2014 Mar-Apr;6(2):523-32
pubmed: 24492296
J Clin Oncol. 1998 Apr;16(4):1310-7
pubmed: 9552031
Cancer Res. 2006 Feb 15;66(4):2328-37
pubmed: 16489038
Blood. 2007 Oct 1;110(7):2537-44
pubmed: 17615291
Cancers (Basel). 2019 Oct 22;11(10):
pubmed: 31652572
Cancer Res. 2012 Jul 15;72(14):3664-76
pubmed: 22628427
Clin Transl Sci. 2021 Nov;14(6):2300-2313
pubmed: 34405542
Expert Opin Ther Targets. 2008 Mar;12(3):341-51
pubmed: 18269343
J Clin Oncol. 2003 Feb 15;21(4):631-7
pubmed: 12586799
N Engl J Med. 2004 Jun 10;350(24):2461-70
pubmed: 15190138
Mol Immunol. 2007 May;44(12):3122-31
pubmed: 17379311
Biotechnol Bioeng. 2004 Sep 5;87(5):614-22
pubmed: 15352059
Curr Opin Oncol. 2011 May;23(3):254-8
pubmed: 21330921
Oncotarget. 2015 May 30;6(15):13462-75
pubmed: 25951351
J Immunother Cancer. 2019 Jun 25;7(1):159
pubmed: 31238988
In Vivo. 2020 Sep-Oct;34(5):2967-2972
pubmed: 32871839
Chin Clin Oncol. 2018 Apr;7(2):15
pubmed: 29764160
Nat Med. 2020 Sep;26(9):1459-1467
pubmed: 32601337
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
J Clin Oncol. 2018 May 10;36(14):1412-1418
pubmed: 29584545
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
Am J Pathol. 1995 Oct;147(4):1152-60
pubmed: 7573360
Leuk Lymphoma. 2009 May;50(5):788-801
pubmed: 19452318
Oncogene. 2005 Mar 24;24(13):2121-43
pubmed: 15789036
Front Immunol. 2017 Dec 21;8:1804
pubmed: 29312320
Oncoimmunology. 2019 Oct 11;9(1):1673635
pubmed: 32002285